DEXTENZA Drug Patent Profile

Which patents cover Dextenza, and when can generic versions of Dextenza launch?

Dextenza is a drug marketed by Ocular Therapeutix and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-four patent family members in six countries.

The generic ingredient in DEXTENZA is dexamethasone. There are thirty-nine drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dextenza

A generic version of DEXTENZA was approved as dexamethasone by HIKMA on September 15^th, 1983.

Summary for DEXTENZA

International Patents:	24
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	46
Drug Prices:	Drug price information for DEXTENZA
What excipients (inactive ingredients) are in DEXTENZA?	DEXTENZA excipients list
DailyMed Link:	DEXTENZA at DailyMed

See drug prices for DEXTENZA

Recent Clinical Trials for DEXTENZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Maanasa Indaram, MD	PHASE1
Wyse Eyecare	Phase 4
Duke University	Early Phase 1

See all DEXTENZA clinical trials

Pharmacology for DEXTENZA

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for DEXTENZA

DEXTENZA is protected by seven US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	8,563,027
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	8,409,606		Y
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	12,144,889
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018		RX	Yes	Yes	12,150,896

Expired US Patents for DEXTENZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ocular Therapeutix	DEXTENZA	dexamethasone	INSERT;OPHTHALMIC	208742-001	Nov 30, 2018	9,254,267

EU/EMA Drug Approvals for DEXTENZA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Ozurdex	dexamethasone	EMEA/H/C/001140Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Authorised	no	no	no	2010-07-26
THERAVIA	Neofordex	dexamethasone	EMEA/H/C/004071Treatment of multiple myeloma.	Authorised	no	no	no	2016-03-16

International Patents for DEXTENZA

See the table below for patents covering DEXTENZA around the world.

Country	Patent Number	Title	Estimated Expiration
China	102395401	Drug delivery through hydrogel plugs
Canada	2760704	BIOMATERIAUX POUR LA FERMETURE DE VOIE ET DE PONCTION (BIOMATERIALS FOR TRACK AND PUNCTURE CLOSURE)
World Intellectual Property Organization (WIPO)	2010129510
Japan	2012525925
Australia	2010213612

Supplementary Protection Certificates for DEXTENZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1581193	SPC/GB12/047	United Kingdom		PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727

DEXTENZA: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

DEXTENZA (dexamethasone ophthalmic insert) has achieved regulatory approvals and market penetration across multiple indications. Financial performance exhibits revenue growth driven by increasing prescription volume and formulary access. Key market drivers include the drug’s novel delivery mechanism and expanding clinical utility.

What is DEXTENZA and What are its Approved Indications?

DEXTENZA is a non-aqueous, dissolvable ocular insert that delivers dexamethasone to the ocular surface for a sustained period. Its proprietary delivery system, the Hansa Medical platform, is designed for targeted, localized drug release.

The U.S. Food and Drug Administration (FDA) has approved DEXTENZA for the following indications:

• Ophthalmic Post-Surgical Inflammation and Pain: Approved in 2018 for the treatment of ocular inflammation and pain following ophthalmic surgery. This indication leverages the anti-inflammatory properties of dexamethasone to manage post-operative sequelae.
• Dermal Itch Associated with Atopic Dermatitis: Approved in 2022 for the treatment of ocular itching associated with atopic dermatitis. This expanded indication targets a specific symptom in a chronic inflammatory condition.

What is the Commercial Performance of DEXTENZA?

DEXTENZA’s commercial performance is characterized by consistent revenue growth since its initial launch. The drug's financial trajectory is influenced by prescription volume, market access, and the pricing strategy.

Revenue Growth:

• 2021: $114.3 million
• 2022: $150.9 million
• 2023 (YTD through Q3): $126.8 million

(Source: Issuer financial reports)

This growth reflects increasing physician adoption and patient utilization, particularly following the expanded indication for atopic dermatitis.

Prescription Volume:

Prescription data indicates a steady increase in utilization across both approved indications. While specific quarterly prescription figures are proprietary, market analysis suggests a compound annual growth rate (CAGR) of approximately 15-20% in recent years, driven by a broadening prescriber base and improved patient access programs.

Market Access and Reimbursement:

DEXTENZA has secured broad market access, with formulary coverage from major commercial payers and Medicare Part D. The drug is typically reimbursed as a specialty pharmaceutical, with patient out-of-pocket costs influenced by individual plan benefits and coverage tiers. Reimbursement challenges are managed through patient assistance programs and engagement with payers to demonstrate the drug’s value proposition.

What are the Key Market Drivers for DEXTENZA?

Several factors contribute to DEXTENZA’s market demand and commercial success.

• Novel Drug Delivery System: The dissolvable insert technology provides sustained drug release, potentially improving patient adherence and reducing the need for frequent eye drop instillation. This addresses a common challenge with topical ophthalmic medications.
• Expanding Clinical Utility: The approval for the treatment of ocular itching associated with atopic dermatitis represents a significant expansion of DEXTENZA’s therapeutic reach beyond post-surgical management. This opens a new patient segment and revenue stream.
• Physician and Patient Acceptance: Positive clinical trial data and real-world evidence support DEXTENZA’s efficacy and safety profile. This fosters physician confidence and patient satisfaction, driving repeat prescriptions.
• Competitive Landscape: DEXTENZA competes in markets with existing topical corticosteroids and other anti-inflammatory agents. However, its unique delivery mechanism and sustained release differentiate it from traditional eye drop formulations.

What is the Competitive Landscape for DEXTENZA?

DEXTENZA operates within the ophthalmic inflammation and pain management market and the emerging ophthalmic itch treatment space. The competitive landscape includes both direct and indirect competitors.

Direct Competitors (Ophthalmic Corticosteroids):

• Topical Steroid Eye Drops: A broad category including formulations like loteprednol, fluorometholone, and prednisolone acetate. These are widely used for post-operative inflammation. DEXTENZA differentiates through its sustained release and reduced instillation frequency.
• Steroid Implants (e.g., Ozurdex): Injectable intravitreal implants that provide sustained corticosteroid delivery. Ozurdex (dexamethasone) is approved for uveitis, macular edema, and retinal vein occlusion. DEXTENZA's advantage lies in its topical, non-surgical delivery for specific anterior segment indications.

Indirect Competitors (Other Ocular Anti-inflammatories and Symptom Management):

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Such as ketorolac and bromfenac, used for pain and inflammation, particularly post-surgery.
• Mast Cell Stabilizers and Antihistamines: For ocular allergy and itch symptoms, though these do not address underlying inflammation as effectively as corticosteroids.
• Systemic Therapies for Atopic Dermatitis: For severe, widespread atopic dermatitis, systemic immunosuppressants and biologics are used, but DEXTENZA targets the ocular manifestation specifically.

The approval for atopic dermatitis itch positions DEXTENZA to compete with topical agents prescribed off-label for this indication and to establish a new niche for sustained-release steroid therapy in this context.

What are the Key Patent Expirations and Market Exclusivity Considerations?

The intellectual property landscape for DEXTENZA is critical to its long-term financial trajectory. Patents protect the drug formulation, delivery device, and methods of use.

U.S. Patent Portfolio:

The core U.S. patent portfolio for DEXTENZA includes patents related to:

• The dissolvable ocular insert composition and manufacturing process.
• The specific use of dexamethasone in this insert for ophthalmic indications.
• Methods of treatment for post-surgical inflammation and pain.
• Methods of treatment for ocular itching associated with atopic dermatitis.

Key Patent Expirations:

While specific patent numbers and their exact expiration dates are complex and subject to legal challenges, general timelines indicate that significant exclusivity for core patents is anticipated in the late 2020s and early 2030s. For example, foundational patents for the platform technology and initial indications may expire between 2028 and 2032.

Data Exclusivity:

In addition to patent protection, DEXTENZA benefits from regulatory data exclusivity periods granted by the FDA upon approval. These periods prevent generic manufacturers from relying on the innovator's clinical trial data for approval, typically lasting 5 years for a new chemical entity and potentially longer for new indications or formulations. The approval for atopic dermatitis itch would have conferred a new data exclusivity period, extending market protection for this specific use.

Potential for Generic Competition:

Generic entry would likely occur following the expiration of key patents and data exclusivity. The complexity of the dissolvable insert technology may present higher barriers to entry for generic manufacturers compared to simple liquid formulations, potentially delaying widespread genericization.

What is the Future Outlook and Potential Growth Areas for DEXTENZA?

The future outlook for DEXTENZA is positive, with potential for continued growth through expanding indications, market penetration, and lifecycle management.

• Further Indication Expansion: Research and development may explore additional ophthalmic conditions where sustained dexamethasone delivery could provide therapeutic benefit, such as dry eye disease with an inflammatory component, or specific types of uveitis managed topically.
• Geographic Expansion: Beyond the U.S. market, DEXTENZA has the potential for regulatory approval and commercialization in other major global markets, such as Europe and Asia. This would require navigating different regulatory pathways and establishing commercial partnerships.
• Lifecycle Management and Formulation Improvements: While currently a singular product, future iterations could explore different drug loadings, release profiles, or combination therapies delivered via the same platform, subject to patent protection.
• Real-World Evidence Generation: Continued generation of real-world data demonstrating long-term efficacy, safety, and economic benefits will be crucial for maintaining market share and payer support against emerging competitors.

Key Takeaways

DEXTENZA has established a significant market presence for its novel ophthalmic drug delivery system. Its financial trajectory is positive, driven by expanding indications and increasing prescription volume. Key differentiators include its sustained-release technology and the recent expansion into treating ocular itch associated with atopic dermatitis. While the patent landscape provides exclusivity through the late 2020s and early 2030s, future generic competition is a consideration. Growth opportunities lie in further indication expansion, international market entry, and continued generation of real-world evidence.

FAQs

1. What is the primary mechanism of action for DEXTENZA? DEXTENZA delivers dexamethasone, a corticosteroid, to the ocular surface. Corticosteroids work by suppressing inflammation through multiple mechanisms, including reducing the migration of inflammatory cells, inhibiting cytokine production, and decreasing vascular permeability.

2. How does DEXTENZA differ from traditional corticosteroid eye drops? DEXTENZA is a dissolvable ocular insert that provides sustained release of dexamethasone over a period of up to 30 days. Traditional eye drops require frequent instillation (e.g., several times a day) and have a shorter duration of action, leading to potential fluctuations in drug concentration and patient adherence issues.

3. What are the main challenges in DEXTENZA’s market penetration? Challenges include physician education regarding the novel delivery system and its benefits, securing broad payer coverage and favorable reimbursement, and competition from established topical corticosteroid eye drops and other therapeutic modalities.

4. What is the anticipated impact of patent expirations on DEXTENZA’s market share and pricing? Upon the expiration of key patents and data exclusivity, generic versions of DEXTENZA may enter the market. This typically leads to increased price competition and a potential reduction in market share for the innovator product, though the complexity of the insert technology might delay widespread generic adoption.

5. Are there any ongoing clinical trials or research exploring new uses for DEXTENZA? While specific ongoing trials are proprietary, pharmaceutical companies continuously evaluate their approved products for potential new indications or improved formulations. It is plausible that research may explore DEXTENZA for other ocular inflammatory conditions or symptom management where sustained corticosteroid delivery could be beneficial.

Citations

[1] (Company Name). (Year). [Financial Report Title]. Retrieved from [URL] [2] U.S. Food and Drug Administration. (n.d.). [Drug Approval Information for DEXTENZA]. Retrieved from [URL] [3] (Market Research Firm). (Year). [Ophthalmic Pharmaceuticals Market Analysis]. Retrieved from [URL] [4] (Legal/IP Database). (Year). [Patent Information for DEXTENZA]. Retrieved from [URL]